Publications by authors named "Jacqueline Kieltyka"
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
Arthritis Rheumatol
December 2021
The discovery of cytokines and their role in immune and inflammatory disease led to the development of a plethora of targeted biologic therapies. Later, efforts to understand mechanisms of cytokine signal transduction led to the discovery of JAKs, which themselves were quickly identified as therapeutic targets. It has been a decade since the first JAK inhibitors (jakinibs) were approved, and there are now 9 jakinibs approved for the treatment of rheumatic, dermatologic, hematologic, and gastrointestinal indications, along with emergency authorization for COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- Janus kinase (JAK) inhibitors are commonly used for treating autoimmune and inflammatory diseases, impacting natural killer (NK) cells and innate lymphoid cells (ILCs).
- Research indicates that in mice, liver ILC1s are less affected by JAK inhibitors compared to NK cells in various organs.
- The study found that JAK inhibition altered genes related to cell cycle and apoptosis in both cell types, but ILC1s were protected by high levels of the antiapoptotic gene Bcl2, suggesting a need for further understanding of these mechanisms for clinical applications.
Article Synopsis
- - Fluorescent cell barcoding (FCB) is a technique that enhances flow cytometry by reducing staining variability, but analysis can vary between operators, highlighting the need for improved standardization.
- - The study introduced a method to assess FCB's variability in T/B cells and monocytes, utilizing statistical analyses and R software to compare conventional and semi-automated data analysis workflows.
- - Results indicated that FCB allows for efficient and reproducible phosphoprotein signaling analysis, and the inclusion of internal controls effectively reduced operator bias, making it a promising tool for clinical trials.